Fernando Jayson Sialana

Fernando Jayson Sialana

Auto-generated profile, based on publicly available information

Fernando Jayson Sialana

The Institute of Cancer Research, London, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2018 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
KVKatalin Völgyi
Katalin Völgyi
KBKata Badics
Kata Badics
FSFernando J. Sialana
Fernando J. Sialana
PGPéter Gulyássy
Péter Gulyássy
EUEdina Brigitta Udvari
Edina Brigitta Udvari
GJGábor Juhász
Gábor Juhász

18 March 2017 in Amino Acids
Verified
Journal Article
Closed access
PDF file
TSTamara Stojanovic
Tamara Stojanovic
MOMichaela Orlova
Michaela Orlova
FSFernando J. Sialana
Fernando J. Sialana
HHHarald Höger
Harald Höger
Stanislav StuchlíkStanislav Stuchlík
Stanislav Stuchlík
GLGert Lubec
Gert Lubec

6 May 2026 in Nature
Verified
Journal Article
Open access
PDF file
EDEric W. Deutsch
Eric W. Deutsch
LKLeron W. Kok
Leron W. Kok
JMJonathan M. Mudge
Jonathan M. Mudge
CVCristian F. Valls
Cristian F. Valls
IJIrwin Jungreis
Irwin Jungreis
SHSebastiaan van Heesch
Sebastiaan van Heesch
A major scientific drive is to characterize the protein-coding genome, which is a primary basis for studying human health. But the fundamental question remains of what has been missed in previous analyses. Over the past decade, the translation of non-canonical open reading frames (ncORFs) has been observed across human cell types and disease states1,2,3, with major implications for biomedical science. However, a key gap in knowledge has been which ncORFs produce small microproteins or alternative protein molecules that contribute to the human proteome. Here we report the collaborative efforts of the TransCODE Consortium4 to produce a consensus landscape of protein-level evidence for ncORFs. We show that about 25% of a set of 7,264 ncORFs gives rise to detectable peptides in a large-scale analysis of 95,520 proteomics experiments. We develop an annotation framework for ncORF-encoded microproteins as human proteins and codify the new conceptual model of ‘peptideins’ as microproteins that have indeterminate potential as functional proteins. To probe the biological implications of peptideins, we create an evolutionary analysis approach, termed ORF relative branch length (ORBL), and determine that evolutionary constraint is common and associates with observation of ncORF-derived peptides. We then characterize a pan-essential cellular phenotype for one peptidein from the OLMALINC long non-coding RNA. Overall, we generate public research tools supported by GENCODE and PeptideAtlas and advance biomedical discovery for understudied components of the human proteome.

23 July 2015 in Proteomics
Verified
Journal Article
Closed access
PDF file
JAJana Aradska
Jana Aradska
TBTanja Bulat
Tanja Bulat
FSFernando J. Sialana
Fernando J. Sialana
Ruth Birner-GrünbergerRuth Birner-Grünberger
Ruth Birner-Grünberger
BEBuchner Erich
Buchner Erich
GLGert Lubec
Gert Lubec

1 January 2019 in Redox Biology
Verified
Journal Article
Open access
MNMarie-Sophie Narzt
Marie-Sophie Narzt
INIonela-Mariana Nagelreiter
Ionela-Mariana Nagelreiter
OOOlga V. Oskolkova
Olga V. Oskolkova
VBValery N. Bochkov
Valery N. Bochkov
JLJulie Latreille
Julie Latreille
FGFlorian Gruber
Florian Gruber
Ultraviolet light is the dominant environmental oxidative skin stressor and a major skin aging factor. We studied which oxidized phospholipid (OxPL) mediators would be generated in primary human keratinocytes (KC) upon exposure to ultraviolet A light (UVA) and investigated the contribution of OxPL to UVA responses. Mass spectrometric analysis immediately or 24 h post UV stress revealed significant changes in abundance of 173 and 84 lipid species, respectively. We identified known and novel lipid species including known bioactive and also potentially reactive carbonyl containing species. We found indication for selective metabolism and degradation of selected reactive lipids. Exposure to both UVA and to in vitro UVA - oxidized phospholipids activated, on transcriptome and proteome level, NRF2/antioxidant response signaling, lipid metabolizing enzyme expression and unfolded protein response (UPR) signaling. We identified NUPR1 as an upstream regulator of UVA/OxPL transcriptional stress responses and found this protein to be expressed in the epidermis. Silencing of NUPR1 resulted in augmented expression of antioxidant and lipid detoxification genes and disturbed the cell cycle, making it a potential key factor in skin reactive oxygen species (ROS) responses intimately involved in aging and pathology.

10 February 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AOAmada R. López de la Oliva
Amada R. López de la Oliva
José Campos-SandovalJosé Campos-Sandoval
José Campos-Sandoval
MGMaría C. Gómez-García
María C. Gómez-García
CCCarolina Cardona
Carolina Cardona
MMMercedes Martín-Rufián
Mercedes Martín-Rufián
JAVIER MARQUEZJAVIER MARQUEZ
JAVIER MARQUEZ
Glutaminase (GA) catalyzes the first step in mitochondrial glutaminolysis playing a key role in cancer metabolic reprogramming. Humans express two types of GA isoforms: GLS and GLS2. GLS isozymes have been consistently related to cell proliferation, but the role of GLS2 in cancer remains poorly understood. GLS2 is repressed in many tumor cells and a better understanding of its function in tumorigenesis may further the development of new therapeutic approaches. We analyzed GLS2 expression in HCC, GBM and neuroblastoma cells, as well as in monkey COS-7 cells. We studied GLS2 expression after induction of differentiation with phorbol ester (PMA) and transduction with the full-length cDNA of GLS2. In parallel, we investigated cell cycle progression and levels of p53, p21 and c-Myc proteins. Using the baculovirus system, human GLS2 protein was overexpressed, purified and analyzed for posttranslational modifications employing a proteomics LC-MS/MS platform. We have demonstrated a dual targeting of GLS2 in human cancer cells. Immunocytochemistry and subcellular fractionation gave consistent results demonstrating nuclear and mitochondrial locations, with the latter being predominant. Nuclear targeting was confirmed in cancer cells overexpressing c-Myc- and GFP-tagged GLS2 proteins. We assessed the subnuclear location finding a widespread distribution of GLS2 in the nucleoplasm without clear overlapping with specific nuclear substructures. GLS2 expression and nuclear accrual notably increased by treatment of SH-SY5Y cells with PMA and it correlated with cell cycle arrest at G2/M, upregulation of tumor suppressor p53 and p21 protein. A similar response was obtained by overexpression of GLS2 in T98G glioma cells, including downregulation of oncogene c-Myc. Furthermore, human GLS2 was identified as being hypusinated by MS analysis, a posttranslational modification which may be relevant for its nuclear targeting and/or function. Our studies provide evidence for a tumor suppressor role of GLS2 in certain types of cancer. The data imply that GLS2 can be regarded as a highly mobile and multilocalizing protein translocated to both mitochondria and nuclei. Upregulation of GLS2 in cancer cells induced an antiproliferative response with cell cycle arrest at the G2/M phase.